Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

ME Bahar, HJ Kim, DR Kim - Signal transduction and targeted therapy, 2023 - nature.com
Metastatic dissemination of solid tumors, a leading cause of cancer-related mortality,
underscores the urgent need for enhanced insights into the molecular and cellular …

Targeting aberrant RAS/RAF/MEK/ERK signaling for cancer therapy

U Degirmenci, M Wang, J Hu - Cells, 2020 - mdpi.com
The RAS/RAF/MEK/ERK (MAPK) signaling cascade is essential for cell inter-and intra-
cellular communication, which regulates fundamental cell functions such as growth, survival …

Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy

Z Eroglu, A Ribas - Therapeutic advances in medical …, 2016 - journals.sagepub.com
Treatment with BRAF inhibitors such as vemurafenib or dabrafenib in patients with
advanced BRAFV600 mutated melanoma has shown objective tumor responses in …

[HTML][HTML] Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance

JA McCubrey, LS Steelman, WH Chappell… - Oncotarget, 2012 - ncbi.nlm.nih.gov
Abstract The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by
genetic alterations in upstream signaling molecules such as receptor tyrosine kinases …

Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update

DR Ciocca, AP Arrigo, SK Calderwood - Archives of toxicology, 2013 - Springer
Heat shock proteins (HSP) are a subset of the molecular chaperones, best known for their
rapid and abundant induction by stress. HSP genes are activated at the transcriptional level …

[HTML][HTML] Pathways and therapeutic targets in melanoma

E Shtivelman, MA Davies, P Hwu, J Yang, M Lotem… - Oncotarget, 2014 - ncbi.nlm.nih.gov
This review aims to summarize the current knowledge of molecular pathways and their
clinical relevance in melanoma. Metastatic melanoma was a grim diagnosis, but in recent …

[HTML][HTML] Regulation of Bim in health and disease

RV Sionov, SA Vlahopoulos, Z Granot - Oncotarget, 2015 - ncbi.nlm.nih.gov
The BH3-only Bim protein is a major determinant for initiating the intrinsic apoptotic pathway
under both physiological and pathophysiological conditions. Tight regulation of its …

Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions

DS Hong, U Banerji, B Tavana, GC George… - Cancer treatment …, 2013 - Elsevier
Due to the critical role of heat shock protein 90 (HSP90) in regulating the stability, activity
and intracellular sorting of its client proteins involved in multiple oncogenic processes …

BRAF inhibitor resistance in melanoma: mechanisms and alternative therapeutic strategies

J Zhong, W Yan, C Wang, W Liu, X Lin, Z Zou… - … Treatment Options in …, 2022 - Springer
Opinion statement Melanoma is caused by a variety of somatic mutations, and among these
mutations, BRAF mutation occurs most frequently and has routinely been evaluated as a …

The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma

A Kim, MS Cohen - Expert opinion on drug discovery, 2016 - Taylor & Francis
Introduction: In the era of precision medicine and sophisticated modern genetics, the
discovery of the BRAFV600 inhibitor, vemurafenib, quickly became the model for targeted …